Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily IV Busulfex Conditioning in Lymphoma
NCT01203020Phase 2Completed
- Sponsor
- West Virginia University
- Start
- Oct 2010
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by West Virginia University. Primary endpoints: Overall Survival at 2 years and Progression Free Survival at 2 years. Started Oct 2010; status: completed.
02
Drugs
busulfan
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01203020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203020.